CN101670102A - 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用 - Google Patents

联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用 Download PDF

Info

Publication number
CN101670102A
CN101670102A CN200910192351A CN200910192351A CN101670102A CN 101670102 A CN101670102 A CN 101670102A CN 200910192351 A CN200910192351 A CN 200910192351A CN 200910192351 A CN200910192351 A CN 200910192351A CN 101670102 A CN101670102 A CN 101670102A
Authority
CN
China
Prior art keywords
hiv vaccine
vector hiv
poxvirus
vaccine
adenoviral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910192351A
Other languages
English (en)
Chinese (zh)
Inventor
陈凌
陈志伟
张林琦
孙彩军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Institute of Biomedicine and Health of CAS
Original Assignee
Guangzhou Institute of Biomedicine and Health of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Institute of Biomedicine and Health of CAS filed Critical Guangzhou Institute of Biomedicine and Health of CAS
Priority to CN200910192351A priority Critical patent/CN101670102A/zh
Publication of CN101670102A publication Critical patent/CN101670102A/zh
Priority to PCT/CN2010/076905 priority patent/WO2011032489A1/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200910192351A 2009-09-15 2009-09-15 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用 Pending CN101670102A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200910192351A CN101670102A (zh) 2009-09-15 2009-09-15 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用
PCT/CN2010/076905 WO2011032489A1 (fr) 2009-09-15 2010-09-14 Procédé d'utilisation d'un vaccin contre le vih à vecteur de poxvirus combiné à un vaccin contre le vih à vecteur adénoviral, et applications correspondantes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910192351A CN101670102A (zh) 2009-09-15 2009-09-15 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用

Publications (1)

Publication Number Publication Date
CN101670102A true CN101670102A (zh) 2010-03-17

Family

ID=42017657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200910192351A Pending CN101670102A (zh) 2009-09-15 2009-09-15 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用

Country Status (2)

Country Link
CN (1) CN101670102A (fr)
WO (1) WO2011032489A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032489A1 (fr) * 2009-09-15 2011-03-24 中国科学院广州生物医院与健康研究院 Procédé d'utilisation d'un vaccin contre le vih à vecteur de poxvirus combiné à un vaccin contre le vih à vecteur adénoviral, et applications correspondantes
WO2013010300A1 (fr) * 2011-07-18 2013-01-24 Zeng Yi Application séquentielle et répétée de quatre vaccins génétiques de vecteur de vih ou davantage
CN107106673A (zh) * 2014-09-03 2017-08-29 巴法里安诺迪克有限公司 用于增强免疫应答的方法和组合物
CN110624106A (zh) * 2018-06-22 2019-12-31 嘉和生物药业有限公司 Pd-1信号通路拮抗剂与艾滋病疫苗的联合应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321694C (zh) * 2005-05-20 2007-06-20 吉林大学 冻干剂型艾滋病重组痘病毒安卡拉株载体疫苗及其制备方法
WO2007102326A1 (fr) * 2006-03-07 2007-09-13 Yokohama City University Induction d'une immunité forte au moyen d'une combinaison d'un vecteur d'adénovirus de type 5/type 35 et vecteur mva de virus vaccinal
CN101219221B (zh) * 2007-01-12 2011-06-15 中国科学院广州生物医药与健康研究院 携带hiv基因的腺病毒载体疫苗
CN101670102A (zh) * 2009-09-15 2010-03-17 中国科学院广州生物医药与健康研究院 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032489A1 (fr) * 2009-09-15 2011-03-24 中国科学院广州生物医院与健康研究院 Procédé d'utilisation d'un vaccin contre le vih à vecteur de poxvirus combiné à un vaccin contre le vih à vecteur adénoviral, et applications correspondantes
WO2013010300A1 (fr) * 2011-07-18 2013-01-24 Zeng Yi Application séquentielle et répétée de quatre vaccins génétiques de vecteur de vih ou davantage
CN107106673A (zh) * 2014-09-03 2017-08-29 巴法里安诺迪克有限公司 用于增强免疫应答的方法和组合物
CN110624106A (zh) * 2018-06-22 2019-12-31 嘉和生物药业有限公司 Pd-1信号通路拮抗剂与艾滋病疫苗的联合应用

Also Published As

Publication number Publication date
WO2011032489A1 (fr) 2011-03-24

Similar Documents

Publication Publication Date Title
AU2018267669B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
Doherty et al. Dissecting the host response to a γ–herpesvirus
García et al. Therapeutic vaccines against HIV infection
Rosario et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
EP2978449B1 (fr) Compositions et méthodes de traitement ou de prévention d'une infection par le virus de l'immunodéficience humaine
Zhang et al. Vaccinia virus-based vector against infectious diseases and tumors
Patterson et al. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
CN101670102A (zh) 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用
Hu et al. Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques
CN101792491B (zh) 一种基于多串联表位的重组腺病毒hiv疫苗及其制备方法
Hu et al. DNA vaccine–induced long-lasting cytotoxic T cells targeting conserved elements of human immunodeficiency virus Gag are boosted upon DNA or recombinant Modified Vaccinia Ankara vaccination
EP2422618A1 (fr) Modèle animal pour l'évaluation de l'efficacité d'un vaccin contre le VIH
Brinckmann et al. Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010
Ye et al. Immunization with a mixture of HIV Env DNA and VLP vaccines augments induction of CD8 T cell responses
WO2018091637A1 (fr) Levures probiotiques en tant que nouveaux vecteurs de vaccination
Harwood et al. Transient T cell expansion, activation, and proliferation in therapeutically vaccinated SIV+ macaques treated with N-803
Wade-Evans et al. Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge
Harwood Evaluating Immune Responses to Therapeutic Vaccination and Correlates of Post-treatment Control in SIV+ Mauritian Cynomolgus Macaques
Yin et al. Viral reservoir is suppressed but not eliminated by CD8 vaccine specific lymphocytes
Chen et al. New strategies for immune-mediated anti-viral drug and vaccine development
Stratov et al. Phenotypic and kinetic analysis of effective simian–human immunodeficiency virus-specific T cell responses in DNA-and fowlpox virus-vaccinated macaques
Muller Anti-vector immune responses to an MVA vaccine
NZ767061B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
Reimann et al. Monica Vaccari, Joseph Mattapallil, Kaimei Song, Wen-Po
NZ767061A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100317